Supported by WILLOW trial findings, the oral TLR 7/8 inhibitor demonstrated significant, dose-dependent reductions in skin disease activity for patients with lupus.

In the INTEGUMENT-INFANT trial, 34.4% of patients achieved vIGA-AD success and 58.3% reached EASI-75 at week 4.

The US launch of Xtoro introduces a novel fluoroquinolone targeting key pathogens in acute otitis externa, delivering rapid ear pain cessation and high clinical cure rates.

Backed by phase 3 RINGSIDE data showing an 84% reduction in the risk of disease progression or death, the investigational agent moves ahead in the regulatory pipeline.

Researchers found that 140 individuals (32.1%) reported lifetime GLP-1 RA use and 96 (22.0%) reported current use. HealthDay ...